NovaDel Pharma Inc.

NovaDel Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2009 [Press Release]
Business Wire | 7 days 1 hour 42 minutes ago
NovaDel Pharma Inc. (the “Company”) (NYSE AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its third quarter and nine months ended September 30, 2009. For the quarter and nine months ended September 30, 2009, NovaDel reported a net loss of $1.4 million, or $0.02 per share, and $5.2 million, or $0.09 per share, respectively, compared to a net loss of $2.5 million, or $0.04 per share, and $...

NovaDel Signs Exclusive License and Distribution Agreement with Hi-Tech Pharmacal Co., Inc. s Subsidiary to Commercialize and Manufacture ZolpiMist in the US and Canada [Press Release]
Business Wire | 7 days 9 hours 9 minutes ago
NovaDel Pharma Inc. (NYSE AMEX: NVD) today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

NovaDel Receives Notice of Allowance for New U.S. Patent Covering its Oral Spray Drug Delivery Technology [Press Release]
Business Wire | 18 days 9 hours 6 minutes ago
NovaDel Pharma Inc. (NYSE AMEX: NVD), today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. Once issued, this patent will expire in 2018.

NovaDel Holds Annual Meeting [Press Release]
Business Wire | 38 days 9 hours 53 minutes ago
NovaDel Pharma Inc. (NYSE AMEX: NVD) held its 2009 Annual Meeting of Stockholders on October 15, 2009. Mr. Mark Baric, Mr. Thomas Bonney, Mr. Steven Ratoff and Dr. Charles Nemeroff were elected directors of the Company. In addition, J.H. Cohn LLP was approved as the Company’s auditors for 2009. Mr. Ratoff, Chairman of the Board, Interim Chief Executive Officer and Interim Chief Financial Officer, reviewed the progress of the Company. Mr. Ratoff noted that NovaDel is actively engaged in licens...

NovaDel Licenses its NitroMist Lingual Spray to Mist [Press Release]
Business Wire | 27 days 2 hours 39 minutes ago
NovaDel Pharma Inc., (NYSE AMEX: NVD) has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris. Under terms of the agreement, Mist will pay NovaDel a $1,000,000 licensing fee upon execution of the agreement, milestone payments totaling an additional $1,000,000 over the next twelve months and o...

Hi-Tech Pharmacal s ECR Subsidiary Signs Exclusive Agreement to Commercialize Sleep Aid in Oral Spray Form [Press Release]
Business Wire | 7 days 9 hours 9 minutes ago
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today the signing of an exclusive licensing agreement between Hi-Tech’s ECR Pharmaceuticals subsidiary and NovaDel Pharma, Inc., a drug development company, through which ECR obtained the rights to market zolpidem tartrate oral spray, 5mg per spray, in the United States and Canada. Under the terms of the agreement ECR paid NovaDel $3 million upon closing. In addition NovaDel will receive a royalty of up to 15% on net sales, and a milestone ...

PicksThatMove.com Announces Investment Opinion On: Human Genome Science Inc., General Electric Company, eBay Inc., NovaDel Pharma Inc., and Amylin Pharmaceuticals Inc. [Press Release]
Business Wire | 21 days 1 hour 46 minutes ago
PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared over 200%. To view some of our profiled stocks, please visit our website at www.picksthatmove.com.